Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
- Conditions
- NSTEMIUnstable AnginaSTEMI
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 4500
- Registration Number
- NCT04718025
- Locations
- 🇵🇱
Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
- Conditions
- Atrial FibrillationPercutaneous Coronary InterventionsAntithrombotic TherapyAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 2230
- Registration Number
- NCT04695106
- Locations
- 🇵🇱
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdańsk, Pomorskie, Poland
Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndromes
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Target Recruit Count
- 1900
- Registration Number
- NCT04630288
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain
🇪🇸Fundación Pública Progreso y Salud, Sevilla, Spain
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT04588727
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 1002
- Registration Number
- NCT04570345
- Locations
- 🇰🇷
Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of
Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Centro Hospitalario La Concepcion
- Target Recruit Count
- 50
- Registration Number
- NCT04567290
- Locations
- 🇲🇽
Hospital La Concepción, Saltillo, Coahuila, Mexico
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 80
- Registration Number
- NCT04483583
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2Coronary Artery Disease
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 105
- Registration Number
- NCT04484259
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
- Conditions
- Unstable Angina
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 72
- Registration Number
- NCT04442919
- Locations
- 🇵🇱
Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz, Kujawsko-Pomorskie, Poland
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
- Conditions
- Blood Loss, SurgicalTicagrelorClopidogrel
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 1097
- Registration Number
- NCT04431349
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Gyeonggido, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.